To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with JavaScript enabled.
This website is not optimized for your browser, as configured.
Collaboration

Patient-Focused Drug Development: A Systematic Approach

Patient Focused Drug Development A Systematic Approach Feature Image

If you’ve been following us for a while, you may have noticed that our blog and Twitter content often points out that clinical research involves a partnership among many groups of people: sponsor companies (such as Lilly), study coordinators and principal investigators at clinical research sites, ethical review boards, and, of course, patients. The image we created on Lilly TrialGuide to illustrate the relationship among these various groups is meant to subtly show that the patient is at the center of clinical research. Who is involved in clinical trials

While health care providers may be experts on the clinical aspects of a given medical condition, patients are experts on what it is like to live with their condition. When we are developing a potential new treatment in a specific disease, we need to understand several key points:

  • What does it mean to the patient to have this disease or condition?
  • What do patients experience with this disease or condition?
  • What would a successful treatment look like from the patient’s perspective?

Patients have a unique viewpoint that can provide insights on the outcomes that matter most to them.

  • Severity and frequency of symptoms
  • Impact on daily function and daily life

PROAdapted Bullets 17Apr2019-01

This approach is aligned with upcoming guidance from the U.S. FDA on Patient-Focused Drug Development, or PFDD. PFDD is a systematic approach to help ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into the development and evaluation of medical products, at all stages along the way.

For example, we often use patient questionnaires in our clinical research studies to collect information from the patient’s perspective. These patient questionnaires are one form of patient-reported outcomes, or PROs. A PRO is defined as “any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else." Understanding the patient’s viewpoint through measures like PROs can be just as important as data we collect through things like laboratory samples (such as blood, urine, stool, or tissue) and imaging results (such as CT, MRI, or PET scans).

Patients are experts on what it is like to live with their condition, and we are making it a priority to listen to them. Drug development is at its best when we include the patient perspective throughout the process.

Tags: PROs,

Recent Articles

CaringForCaregivers FeatureImage 17Nov2020

Caring for Caregivers

Susan Gilchrist headshot square
Susan Gilchrist
November 18th, 20204 minute read

Read more for services and support groups to make life a bit easier for caregivers - the unsung heroes in the clinical trial process.

YourQuestionsAboutAlzheimersAnswered FeatureImage 21Sept2020

Your questions about Alzheimer’s research, answered

Susan Gilchrist headshot square
Susan Gilchrist
November 17th, 20205 minute read

Considering clinical trial participation may feel overwhelming. Here are some answers to common questions about Alzheimer’s and dementia clinical trials to support you through the learning curve.

ListenToTheYouthVoiceForPatientCentricPediatricDrugDevelopment FeatureImage 21Sept2020-01

Listen to the youth voice for patient-centric pediatric drug development

LTGBlogAuthors LillyGuestAuthorIcon 20July2018
Lilly Guest Author
September 24th, 20204 minute read

The patient voice is critical for successful clinical research, for people of all ages. Learn how Lilly’s partnership with iCAN helps us include that voice in research.

LeapingIntoDecentralizedClinicalTrials FeatureImage 16Sept2020-01

Leaping into Decentralized Clinical Trials

LTGBlogAuthors GuestAuthorIcon 20July2018
Guest Author
September 17th, 20203 minute read

Before starting medical school, Iman Mahoui joined Lilly’s Decentralized Trials team. She reflects on how new approaches to research can help address social justice and health equity issues.

MasterProtocol FeatureImage 14July2020-01

Platform Trials and Master Protocols: A New Approach to Clinical Research

Leigh Anne Naas Headshot
Leigh Anne Naas
August 18th, 20205 minute read

Learn more about platform trials and master protocols, an alternative model to how we conduct clinical research.